Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS

Assenagon Asset Management S.A. increased its stake in Glaukos Corporation (NYSE:GKOS) by 15.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,393 shares of the medical instruments supplier’s stock after purchasing an additional 24,848 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.32% of Glaukos worth $20,594,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AustralianSuper Pty Ltd raised its position in Glaukos by 10.8% during the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after buying an additional 43,750 shares during the period. JPMorgan Chase & Co. grew its stake in Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after acquiring an additional 27,646 shares in the last quarter. Riverbridge Partners LLC increased its holdings in shares of Glaukos by 41.0% in the 3rd quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after purchasing an additional 165,673 shares during the period. Holocene Advisors LP lifted its position in shares of Glaukos by 40.1% in the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock worth $108,030,000 after purchasing an additional 299,118 shares in the last quarter. Finally, TD Asset Management Inc acquired a new stake in shares of Glaukos during the third quarter worth approximately $1,157,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling

In other Glaukos news, CFO Alex R. Thurman sold 1,521 shares of the business’s stock in a transaction dated Tuesday, March 24th. The stock was sold at an average price of $105.24, for a total value of $160,070.04. Following the completion of the sale, the chief financial officer owned 46,498 shares of the company’s stock, valued at $4,893,449.52. The trade was a 3.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 10,498 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total value of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares of the company’s stock, valued at approximately $11,793,290.88. This trade represents a 10.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 322,146 shares of company stock valued at $37,424,948. 5.80% of the stock is owned by corporate insiders.

Glaukos Stock Performance

GKOS stock opened at $108.19 on Friday. The firm has a 50 day moving average of $113.29 and a two-hundred day moving average of $101.82. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $130.23. The company has a market capitalization of $6.28 billion, a price-to-earnings ratio of -33.19 and a beta of 0.70. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm’s revenue for the quarter was up 35.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.40) EPS. As a group, equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

GKOS has been the topic of a number of research analyst reports. Truist Financial boosted their price objective on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Piper Sandler reissued an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. UBS Group boosted their price target on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. BTIG Research reaffirmed a “buy” rating and issued a $131.00 price target on shares of Glaukos in a research note on Wednesday, February 18th. Finally, Wells Fargo & Company increased their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.